TVTX
Travere Therapeutics, Inc.NASDAQHealthcare$30.44-3.12%ClosedMarket Cap: $2.81B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
25.03
P/S
5.98
EV/EBITDA
143.24
DCF Value
$-365.86
FCF Yield
0.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.2%
Operating Margin
-12.8%
Net Margin
-10.2%
ROE
-79.2%
ROA
-8.3%
ROIC
-13.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $129.7M | 84.0% | $-32.4M | $-22.0M | $-0.24 | — |
| FY 2025 | $490.7M | 85.5% | $-62.8M | $-50.3M | $-0.56 | — |
| Q3 2025 | $164.9M | 99.0% | $24.9M | $25.7M | $0.25 | — |
| Q2 2025 | $114.4M | 98.7% | $-12.7M | $-12.8M | $-0.14 | — |
| Q1 2025 | $81.7M | 94.3% | $-42.7M | $-41.2M | $-0.47 | — |
| Q4 2024 | $74.8M | 96.6% | $-60.7M | $-60.3M | $-0.73 | — |
| FY 2024 | $233.2M | 96.7% | $-323.8M | $-321.5M | $-4.08 | — |
| Q3 2024 | $62.9M | 97.4% | $-56.1M | $-54.8M | $-0.70 | — |
| Q2 2024 | $54.1M | 77.1% | $-67.1M | $-70.4M | $-0.91 | — |
| Q1 2024 | $41.4M | 96.4% | $-139.2M | $-136.1M | $-1.76 | — |
| Q4 2023 | $45.1M | 63.6% | $-82.8M | $-90.2M | $-1.18 | — |
| FY 2023 | $145.2M | 92.1% | $-388.1M | $-111.4M | $-1.50 | — |